EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TRAIL ‐ PEG ‐Apt‐ PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik iD

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2026. Verfasst von Gulen Melike Demirbolat und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Technology, Faculty of Pharmacy, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Polyethylene Glycols, TNF-Related Apoptosis-Inducing Ligand, Aptamers, Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Adnan Menderes Üniversitesi, Türkiye Sağlık Enstitüleri Başkanlığı, Türkiye Bilimler Akademisi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted drug therapy is very important for the treatment of triple‐negative breast cancer ( TNBC ), and the development of carrier systems to deliver apoptosis‐inducing proteins such as TRAIL to cells is important in cancer therapy. In this study, a nanosystem formulation ( TRAIL ‐ PEG ‐Apt‐ PLGA ) encapsulating TNBC ‐targeted aptamer‐bound‐ TRAIL protein was performed and the efficacy of this system was evaluated in a mouse tumor model. The characterization of TRAIL ‐ PEG ‐Apt‐ PLGA was confirmed by FTIR , NTA and SEM microscopy. The efficacy of TRAIL ‐ PEG ‐Apt‐ PLGA was evaluated by in vitro release assays and interactions with TNBC cells ( MDA ‐ MB ‐231) and healthy breast cells ( MCF‐10A ). TRAIL ‐ PEG ‐Apt‐ PLGA was administered intravenously to NOD / SCID gamma mouse breast tumors and evaluated in vivo . Pharmacokinetics, bioavailability testing, histological staining ( DR4 / DR5 , TUNEL , HE staining) and molecular alterations with PCR array were evaluated in tumor tissues. TRAIL ‐ PEG ‐Apt‐ PLGA induced apoptosis in both in vivo and in vitro studies. It was found that it regulated cellular responses along with apoptotic mechanisms in cells without developing resistance in suppressing tumor growth by making changes on Atf2, Casp8, Bcl2 and Irf5 genes and proteins. As a result, the biotechnological drug potential of TRAIL was discovered in an aptamer‐bound nanosystem for the treatment of triple‐negative breast cancer and innovative applications for clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPolyethylene GlycolsTNF-Related Apoptosis-Inducing LigandAptamers, NucleotideDrug Delivery SystemsNanoparticlesPolyestersAnimalsHumansFemaleMiceCell Line, TumorApoptosisMDA-MB-231 CellsMice, SCIDMice, Inbred NODDisease Models, Animal

Stichwörter der Autor:innen

PLGA copolymersTRAILaptamersbreast cancertargeted therapy

Substanzen

Polyethylene GlycolsTNF-Related Apoptosis-Inducing LigandAptamers, NucleotidePolyesters

Autor:innen und Institutionen

  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
  • Department of Molecular Biotechnology, Graduate School of Health Sciences, Aydin Adnan Menderes University, Turkey.
  • Department of Medicinal Biochemistry, School of Medicine, Gaziantep Islam Science and Technology University, Turkey.
  • Animal Application and Research Center, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
  • Department of Histology and Embryology, School of Medicine, Aydin Adnan Menderes University, Turkey.
  • Department of Machine and Metal Technologies, Kocarli Vocational School, Aydin Adnan Menderes University, Turkey.

ORCID-Profile: Ozge Cevik

Förderung

  • Adnan Menderes Üniversitesi
  • Türkiye Sağlık Enstitüleri Başkanlığı
  • Türkiye Bilimler Akademisi

Zitieren

APA

Demirbolat, G. M., Kucuk, A., Erdogan, O., Ozer, S., Kozan, B., Cuceli, T., Gumus, E., Cevik, E., & Cevik, O. (2026). TRAIL ‐ PEG ‐Apt‐ PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model. Molecular Oncology. https://doi.org/10.1002/1878-0261.70202

Vancouver

Demirbolat GM, Kucuk A, Erdogan O, Ozer S, Kozan B, Cuceli T, et al. TRAIL ‐ PEG ‐Apt‐ PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model. Molecular Oncology. 2026. doi:10.1002/1878-0261.70202

BibTeX
@article{Demirbolat2026,
  author = {Demirbolat, Gulen Melike and Kucuk, Aslihan and Erdogan, Omer and Ozer, Samed and Kozan, Bensu and Cuceli, Tugba and Gumus, Erkan and Cevik, Evrim and Cevik, Ozge},
  title = {TRAIL ‐ PEG ‐Apt‐ PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70202}
}
Kostenlos starten →